Phosphate binders for preventing and treating bone disease in chronic kidney disease patients

Retardation of Progression of Chronic Kidney Disease Through Pharmacological Interventions

“…In the present study all the phosphate binders have been found to be equally effective in terms of phosphate control if given in equivalent doses for the management of hyperphosphatemia in patients with CKD of both the groups 15 .…”

Retardation of Progression of Chronic Kidney Disease Through Pharmacological Interventions

“…In the present study all the phosphate binders have been found to be equally effective in terms of phosphate control if given in equivalent doses for the management of hyperphosphatemia in patients with CKD of both the groups 15 .…”

Sevelamer Carbonate and Lanthanum Usage Evaluation and Cost Considerations at a Veteran's Affairs Medical Center

“…While phosphorus control trended in favor of sevelamer carbonate in this population, there was no statistically significant difference to refute conclusions of both agents achieving similar phosphorus control as shown in previous studies. 5,10,11 Although lanthanum and sevelamer carbonate are only approved in ESRD patients, this evaluation along with previous literature support use in CKD stage 3-5 as well. 5,17 Both groups included a similar portion of patients who had active prescriptions for calcium acetate.…”

“…5,10,11 Although lanthanum and sevelamer carbonate are only approved in ESRD patients, this evaluation along with previous literature support use in CKD stage 3-5 as well. 5,17 Both groups included a similar portion of patients who had active prescriptions for calcium acetate. While this could represent a confounding variable given that calcium acetate is a first-line phosphate binder, this portion may be artificially elevated because prescriptions remain active for 1 year from the date written.…”

Hyperphosphatemia is required for initiation but not propagation of kidney failure-induced calcific aortic valve disease

“…Importantly, in all of these animal studies, medications were provided at the initiation of the study protocol and, therefore, assessed the impact of the proposed intervention in preventing ectopic calcification but not in treating established calcification. Furthermore, clinical trials failed to show the benefit of phosphate binders on improving cardiovascular outcomes in a dialysis population (14,15). This observation might be at least partially explained by our find- Values are means Ϯ SE.…”

Retardation of Progression of Chronic Kidney Disease Through Pharmacological Interventions

“…In the present study all the phosphate binders have been found to be equally effective in terms of phosphate control if given in equivalent doses for the management of hyperphosphatemia in patients with CKD of both the groups 15 .…”

Sevelamer Carbonate and Lanthanum Usage Evaluation and Cost Considerations at a Veteran's Affairs Medical Center

“…While phosphorus control trended in favor of sevelamer carbonate in this population, there was no statistically significant difference to refute conclusions of both agents achieving similar phosphorus control as shown in previous studies. 5,10,11 Although lanthanum and sevelamer carbonate are only approved in ESRD patients, this evaluation along with previous literature support use in CKD stage 3-5 as well. 5,17 Both groups included a similar portion of patients who had active prescriptions for calcium acetate.…”

“…5,10,11 Although lanthanum and sevelamer carbonate are only approved in ESRD patients, this evaluation along with previous literature support use in CKD stage 3-5 as well. 5,17 Both groups included a similar portion of patients who had active prescriptions for calcium acetate. While this could represent a confounding variable given that calcium acetate is a first-line phosphate binder, this portion may be artificially elevated because prescriptions remain active for 1 year from the date written.…”

Hyperphosphatemia is required for initiation but not propagation of kidney failure-induced calcific aortic valve disease

“…Importantly, in all of these animal studies, medications were provided at the initiation of the study protocol and, therefore, assessed the impact of the proposed intervention in preventing ectopic calcification but not in treating established calcification. Furthermore, clinical trials failed to show the benefit of phosphate binders on improving cardiovascular outcomes in a dialysis population (14,15). This observation might be at least partially explained by our find- Values are means Ϯ SE.…”

Retardation of Progression of Chronic Kidney Disease Through Pharmacological Interventions

“…In the present study all the phosphate binders have been found to be equally effective in terms of phosphate control if given in equivalent doses for the management of hyperphosphatemia in patients with CKD of both the groups 15 .…”

Sevelamer Carbonate and Lanthanum Usage Evaluation and Cost Considerations at a Veteran's Affairs Medical Center

“…While phosphorus control trended in favor of sevelamer carbonate in this population, there was no statistically significant difference to refute conclusions of both agents achieving similar phosphorus control as shown in previous studies. 5,10,11 Although lanthanum and sevelamer carbonate are only approved in ESRD patients, this evaluation along with previous literature support use in CKD stage 3-5 as well. 5,17 Both groups included a similar portion of patients who had active prescriptions for calcium acetate.…”

“…5,10,11 Although lanthanum and sevelamer carbonate are only approved in ESRD patients, this evaluation along with previous literature support use in CKD stage 3-5 as well. 5,17 Both groups included a similar portion of patients who had active prescriptions for calcium acetate. While this could represent a confounding variable given that calcium acetate is a first-line phosphate binder, this portion may be artificially elevated because prescriptions remain active for 1 year from the date written.…”

Hyperphosphatemia is required for initiation but not propagation of kidney failure-induced calcific aortic valve disease

“…Importantly, in all of these animal studies, medications were provided at the initiation of the study protocol and, therefore, assessed the impact of the proposed intervention in preventing ectopic calcification but not in treating established calcification. Furthermore, clinical trials failed to show the benefit of phosphate binders on improving cardiovascular outcomes in a dialysis population (14,15). This observation might be at least partially explained by our find- Values are means Ϯ SE.…”